| Title | Current Cancer Drug Targets |
| Abbreviation | Curr. Cancer Drug Targets |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Drug Discovery (Q2); Pharmacology (Q2); Cancer Research (Q3); Oncology (Q3) |
| h-index | 99 |
| Overall Rank/Ranking | 7275 |
| SCImago Journal Rank (SJR) | 0.687 |
| Impact Score | 2.95 |
| Publisher | Bentham Science Publishers B.V. |
| Country | United Arab Emirates |
| ISSN | 15680096, 18735576 |
| Best Quartile | Q2 |
| Coverage History | 2001-2022 |
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Current Cancer Drug Targets publishes original research articles and a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
Current Cancer Drug Targets is a journal covering the technologies/fields/categories related to Drug Discovery (Q2); Pharmacology (Q2); Cancer Research (Q3); Oncology (Q3). It is published by Bentham Science Publishers B.V.. The overall rank of Current Cancer Drug Targets is 7275. According to SCImago Journal Rank (SJR), this journal is ranked 0.687. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 99. The best quartile for this journal is Q2.
The ISSN of Current Cancer Drug Targets journal is 15680096, 18735576. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Current Cancer Drug Targets is cited by a total of 723 articles during the last 3 years (Preceding 2022).
The Impact IF 2022 of Current Cancer Drug Targets is 2.95, which is computed in 2023 as per its definition. Current Cancer Drug Targets IF is increased by a factor of 0.2 and approximate percentage change is 7.27% when compared to preceding year 2021, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2022 of Current Cancer Drug Targets is 2.95. If the same upward trend persists, Impact IF may rise in 2023 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 2.95 |
| 2021 | 2.75 |
| 2020 | 3.06 |
| 2019 | 2.60 |
| 2018 | 2.15 |
| 2017 | 2.20 |
| 2016 | 2.81 |
| 2015 | 4.16 |
| 2014 | 3.87 |
Current Cancer Drug Targets has an h-index of 99. It means 99 articles of this journal have more than 99 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Current Cancer Drug Targets is 15680096, 18735576. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Current Cancer Drug Targets is 7275. According to SCImago Journal Rank (SJR), this journal is ranked 0.687. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 0.687 |
| 2021 | 0.732 |
| 2020 | 0.972 |
| 2019 | 0.893 |
| 2018 | 0.875 |
| 2017 | 0.951 |
| 2016 | 1.271 |
| 2015 | 1.569 |
| 2014 | 1.533 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 7275 |
| 2021 | 6467 |
| 2020 | 4558 |
| 2019 | 5118 |
| 2018 | 5252 |
| 2017 | 4672 |
| 2016 | 3059 |
| 2015 | 2199 |
| 2014 | 2219 |
Current Cancer Drug Targets is published by Bentham Science Publishers B.V.. It's publishing house is located in United Arab Emirates. Coverage history of this journal is as following: 2001-2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Current Cancer Drug Targets is Curr. Cancer Drug Targets. This abbreviation ('Curr. Cancer Drug Targets') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Drug Discovery (Q2); Pharmacology (Q2); Cancer Research (Q3); Oncology (Q3), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Current Cancer Drug Targets latest impact IF is 2.95. It's evaluated in the year 2022. The highest and the lowest impact IF or impact score of this journal are 4.16 (2015) and 2.15 (2018), respectively, in the last 9 years. Moreover, its average IS is 2.95 in the previous 9 years.
The Current Cancer Drug Targets has an SJR (SCImago Journal Rank) of 0.687, according to the latest data. It is computed in the year 2023. In the past 9 years, this journal has recorded a range of SJR, with the highest being 1.569 in 2015 and the lowest being 0.687 in 2022. Furthermore, the average SJR of the Current Cancer Drug Targets over the previous 9-year period stands at 2.95.
The latest h-index of the Current Cancer Drug Targets is 99.
The Current Cancer Drug Targets is published by the Bentham Science Publishers B.V., with its country of publication being the United Arab Emirates.
The Current Cancer Drug Targets is currently ranked 7275 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 9 years, this journal has experienced varying rankings, reaching its highest position of 2199 in 2015 and its lowest position of 7275 in 2022.
The standard ISO4 abbreviation for the Current Cancer Drug Targets is Curr. Cancer Drug Targets.
Current Cancer Drug Targets is classified as a journal that the Bentham Science Publishers B.V. publishes.
The Current Cancer Drug Targets encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Current Cancer Drug Targets is assigned the following International Standard Serial Numbers (ISSN): 15680096, 18735576.
The best quartile for the Current Cancer Drug Targets is Q2 (2022).
The Current Cancer Drug Targets coverage history can be summarized as follows: 2001-2022.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Milan Journal of Mathematics | journal | 3120 | Birkhauser Verlag Basel | 28 | 1.79 |
| International Journal of Applied Linguistics | journal | 7321 | Wiley-Blackwell Publishing Ltd | 51 | 2.00 |
| Modern Language Journal | journal | 918 | Wiley-Blackwell | 103 | 3.89 |
| British Journal of Special Education | journal | 12024 | Wiley-Blackwell Publishing Ltd | 42 | 1.24 |
| International Journal of Research and Method in Education | journal | 5180 | Taylor and Francis Ltd. | 34 | 2.49 |
| Exploration Geophysics | journal | 16383 | Taylor and Francis Ltd. | 48 | 1.17 |
| Built Environment | journal | 12797 | Alexandrine Press | 43 | 1.15 |
| Oral Radiology | journal | 9461 | Springer Japan | 20 | 2.06 |
| Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining | conference and proceedings | 4334 | 192 | 0.00 | |
| European Journal of Cancer, Supplement | journal | 9063 | Elsevier Ltd. | 28 | 1.93 |
| Year | Impact Score (IS) |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 2.95 |
| 2021 | 2.75 |
| 2020 | 3.06 |
| 2019 | 2.60 |
| 2018 | 2.15 |
| 2017 | 2.20 |
| 2016 | 2.81 |
| 2015 | 4.16 |
| 2014 | 3.87 |
